• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    12/15/23 4:31:40 PM ET
    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ADAP alert in real time by email

    Gainers

    • Alaunos Therapeutics (NASDAQ:TCRT) stock rose 20.9% to $0.06 during Friday's after-market session. The company's market cap stands at $13.2 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares rose 11.98% to $0.27. The company's market cap stands at $6.4 million.
    • I-MAB (NASDAQ:IMAB) shares increased by 7.19% to $1.49. The company's market cap stands at $123.1 million.
    • Genprex (NASDAQ:GNPX) stock rose 6.63% to $0.23. The company's market cap stands at $13.3 million.
    • Ikena Oncology (NASDAQ:IKNA) shares rose 6.59% to $2.1. The company's market cap stands at $101.3 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock increased by 6.22% to $0.48. The market value of their outstanding shares is at $108.5 million.

    Losers

    • Minerva Surgical (NASDAQ:UTRS) stock declined by 13.1% to $2.45 during Friday's after-market session. The company's market cap stands at $21.7 million.
    • Procaps Gr (NASDAQ:PROC) stock fell 12.34% to $2.7. The market value of their outstanding shares is at $304.6 million.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) shares fell 9.99% to $0.35. The market value of their outstanding shares is at $4.1 million.
    • Asensus Surgical (AMEX:ASXC) shares declined by 9.68% to $0.28. The market value of their outstanding shares is at $74.0 million.
    • Intensity Therapeutics (NASDAQ:INTS) shares fell 8.94% to $7.34. The company's market cap stands at $100.6 million.
    • Forte Biosciences (NASDAQ:FBRX) shares declined by 8.11% to $0.69. The company's market cap stands at $25.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $ASXC
    $FBRX
    $GNPX

    CompanyDatePrice TargetRatingAnalyst
    Forte Biosciences Inc.
    $FBRX
    11/25/2025$65.00Outperform
    Evercore ISI
    I-MAB
    $IMAB
    10/3/2025$9.00Outperform
    Leerink Partners
    I-MAB
    $IMAB
    9/9/2025$7.00Buy
    BTIG Research
    Forte Biosciences Inc.
    $FBRX
    8/18/2025$75.00Buy
    Guggenheim
    Adaptimmune Therapeutics plc
    $ADAP
    7/29/2025Buy → Neutral
    H.C. Wainwright
    Adaptimmune Therapeutics plc
    $ADAP
    6/26/2025$0.50Outperform → Neutral
    Mizuho
    Forte Biosciences Inc.
    $FBRX
    1/21/2025Buy
    TD Cowen
    Adaptimmune Therapeutics plc
    $ADAP
    7/30/2024$4.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Riley Antony A bought $254,833 worth of shares (9,680 units at $26.33), converted options into 375 shares and covered exercise/tax liability with 154 shares, increasing direct ownership by 31% to 41,741 units (SEC Form 4)

    4 - Forte Biosciences, Inc. (0001419041) (Issuer)

    1/2/26 4:04:43 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:51:45 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:47:09 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    SEC Filings

    View All

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    3/18/26 7:03:51 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intensity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

    3/6/26 8:04:30 AM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intensity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

    3/5/26 8:07:23 AM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 7,168 shares, decreasing direct ownership by 25% to 21,692 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/27/26 6:34:18 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 9,330 shares, decreasing direct ownership by 20% to 36,331 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/27/26 6:33:20 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Vieser Jaime was granted 5,839 shares, increasing direct ownership by 22% to 32,338 units (SEC Form 4)

    4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

    1/15/26 4:15:02 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Forte Biosciences with a new price target

    Evercore ISI initiated coverage of Forte Biosciences with a rating of Outperform and set a new price target of $65.00

    11/25/25 8:42:19 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on I-Mab with a new price target

    Leerink Partners initiated coverage of I-Mab with a rating of Outperform and set a new price target of $9.00

    10/3/25 8:40:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on I-Mab with a new price target

    BTIG Research initiated coverage of I-Mab with a rating of Buy and set a new price target of $7.00

    9/9/25 7:57:49 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

    Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyREQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung CancerREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, March 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators

    3/18/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

    Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 25,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting

    3/17/26 4:01:00 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

    Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ("Cohort A") achieved a pathological complete response ("pCR") whereas two (2) out of six (6) (33%) patients in the SOC arm alone ("Cohort B") achieved a pCR, with one patient still to be evaluated. Forty-four percent (44%) fewer grade 3 or higher Adverse Events ("AEs") were observed in Cohort A compared to Cohort B.A protocol amendment has been submitted to the Swiss Agency for Therapeutic Products ("Swissmedic"), Switzerland's regulatory authority, and the Swiss Ethics Committee to resume enrollment.SHELTON, Conn., March 1

    3/12/26 7:30:00 AM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

    SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

    12/6/24 4:05:50 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ikena Oncology Inc.

    SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

    11/14/24 5:05:17 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Financials

    Live finance-specific insights

    View All

    Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

    The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety The manuscript is open access The Company will host a webinar with the paper's lead and senior authors from the University of Southern California to discuss the results on Friday, October 31, 2025, at 9:00 AM (see below) SHELTON, Conn., Oct. 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that

    10/30/25 7:30:00 AM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

    Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with GalapagosPurchase price is $55m in cash to be paid upon consummation of the sale with up to $30m in potential future payments upon achievement of certain milestonesAdaptimmune will retain rights to its preclinical assets including PRAME, CD70, and its allogeneic program Adaptimmune will restructure to support the transition of these therapies to US WorldMeds and to maximize value from its remaining assetsAdaptimmune's Board of Directors determined this transaction is in the best interest of all stakeholders follow

    7/28/25 7:30:00 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

    Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the

    6/23/25 7:18:00 AM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ASXC
    $FBRX
    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

    Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC)Mr. Wei Fu, I-Mab's Chairman of the Board of Directors, appointed as Executive Chairman, supported by further executive additions ROCKVILLE, Md., Sept. 08, 2025 (GLOBE N

    9/8/25 8:30:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

    Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of

    8/25/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care